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Background/Aims: Studies concerning red cell distribu-
tion width (RDW) for use in the assessment of inﬂ  ammatory 
bowel disease (IBD) activity are limited. We investigated 
whether RDW is a marker of active disease in patients with 
IBD. Methods: In total, 61 patients with ulcerative colitis (UC) 
and 56 patients with Crohn’s disease (CD) were enrolled 
in the study group, and 44 age- and-sex-matched healthy 
volunteers were included as the control group. A CD activ-
ity index >150 in patients with CD indicated active disease. 
Patients with moderate and severe disease based on the 
Truelove-Witts criteria were considered to have active UC. In 
addition to RDW, serum C-reactive protein levels, erythrocyte 
sedimentation rates, and platelet counts were measured. 
Results: Twenty-nine (51.7%) patients with CD and 35 (57.4%) 
patients with UC had active disease. The RDW was signifi-
cantly higher in patients with CD and UC than in controls 
(p<0.001 and p<0.001, respectively). A subgroup analysis 
indicated that for a RDW cut-off of 14%, the sensitivity for de-
tecting active CD was 79%, and the specicity was 93% (area 
under curve [AUC], 0.935; p<0.001). RDW was the most sen-
sitive and speciﬁ  c marker for active CD. However, it was not 
valid for UC, as the ESR at a cutoff of 15.5 mm/hr showed 
a sensitivity of 83% and a specicity of 76% (AUC, 0.817; 
p<0.001), whereas the RDW at a cutoff of 14% showed 17% 
sensitivity and 84% specicity for detecting active UC. Conclu-
sions: RDW was elevated in IBD in comparison with healthy 
controls and increased markedly in active disease. RDW may 
be a sensitive and speciﬁ  c marker for determining active CD, 
whereas ESR is an important marker of active UC. (Gut Liver 
2011;5:460-467)
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INTRODUCTION
Inflammatory bowel disease (IBD) encompasses a group of 
chronic inflammatory diseases with unknown etiology that are 
characterized by recurring remission and exacerbation periods. 
Recent studies have demonstrated that both the prevalence 
of IBD and the hospitalization of IBD patients are increasing.
1 
For the determination of disease activity in IBD patients, both 
noninvasive laboratory parameters and endoscopic procedures 
are currently used to diagnose the disease and to determine 
the extent of disease involvement and activation.
2 However, 
endoscopic procedures are both expensive and invasive.
3 Other 
assays used to determine inflammation in IBD patients that 
have been assessed in previous studies include alterations in the 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) 
levels, albumin levels, hemoglobin (Hgb) levels and platelet 
counts (PLT) as well as the measurement of serum concentra-
tions of interleukin-6, interleukin-1, soluble interleukin-2 re-
ceptor and soluble intercellular adhesion molecule-1 (ICAM-1). 
However, the sensitivity and specificity of these tests for moni-
toring IBD disease activity are low.
4-8 For the determination of 
mucosal inflammation, the use of a highly sensitive, highly spe-
cific radioactively labeled leukocyte assay on feces is impractical 
and exposes patients to radiation.
9 As revealed in recent studies, 
high-sensitivity and high-specificity tests, such as fecal calpro-
tectin, lactoferrine and polymorphonuclear neutrophil elastase 
tests, are expensive and are not available at many medical 
centers.
10,11 Therefore, there is a need for a new way to test for 
IBD disease activity that is highly specific yet cost-effective and 
not overly invasive or potentially harmful to patients. Previous 
studies in patients with normal hemoglobin levels have demon-
strated that the red cell distribution width (RDW) is a valuable 
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of celiac patients on a gluten-free diet.
12,13 The purpose of this 
study was to determine whether the RDW could also be used as 
a marker to assess disease activation in IBD patients.
MATERIALS AND METHODS
1. Selection of study participants
This is a cross sectional observational cohort study performed 
in Department of Gastroenterology, Haydarpaşa Numune Edu-
cation and Research Hospital. A total of 117 consecutive IBD 
patients with ages ranging from 18 to 70 years participated in 
the study. These patients were diagnosed with IBD that was 
clinically, endoscopically, radiologically and histopathologically 
confirmed. Furthermore, the clinical and laboratory parameters 
of these patients were reviewed to confirm their diagnosis. In 
addition to the IBD patients, 44 healthy control subjects, who 
were matched with the patients in terms of age and gender, 
participated in the study. For the selection of the control group, 
subjects were chosen who had no known disease, did not use 
medication or transfusion treatments and did not have any 
immediate family members with IBD. All participants were in-
queried for any constitutional symptoms those may be confused 
with IBDs and any participant  positive for these symptoms 
were exluded from this study. Subjects with any inflammatory 
diseases, anemia, or malignancies were carefully excluded from 
the present study. All subjects included in the control group 
were judged to be in good health, with normal results on liver 
function tests, acute phase reactants (such as CRP, ESR) and 
confirmed as having normal findings  by transabdominal  ul-
trasound. Subjects who were taking any medication were not 
included in the control group. The study protocol was approved 
by our local Ethics Committee and all subjects gave their writ-
ten informed consent to participate in the study.
Patients were diagnosed with IBD (ulcerative colitis [UC] 
or Crohn’s disease [CD]) and further divided into 2 subgroups 
based on their disease activation state (either “active” or “in re-
mission”). The UC patients were categorized using the Truelove-
Witts criteria, and patients with CD were categorized using the 
CD activity index (CDAI) criteria. Patients were considered to be 
in the “active” disease state if they had medium-severe activity 
based on Truelove-Witts criteria or a CDAI greater than 150 for 
UC and CD, respectively.
Hematological parameters, including Hgb (range, 14 to 18 g/
dL for men, 12 to 16 g/dL for women), white blood cell count 
(WBC; range, 4,000 to 10,000/mm), PLT count (range, 150,000 
to 450,000/mm), and RDW (range, 11% to 14%), were analyzed 
by standard methods. ESR was estimated by Westergen method. 
The threshold levels for ESR, and CRP were 20 mm/hr, and 0.8 
mg/dL, respectively.
The age, gender, disease location and duration, and disease 
activity of each patient were determined. All enrolled patients 
were asked to take hemogram tests. Routine hemogram pa-
rameters, CRP and ESR values and inflammatory markers were 
assessed. First, comparisons of the RDW values from the IBD 
patients were made between the UC, CD, and healthy control 
groups. Then, the patients were grouped based on their disease 
activation states, and the RDW levels were compared between 
the active and remission period subgroups within each disease. 
Finally, ESR and CRP levels were compared among the groups 
and crosswise with the control group.
2. Statistical evaluation
SPSS for Windows version 15.0 (SPSS Inc, Chicago, IL, 
USA) was used for the statistical analyses. For the evaluation 
of the study data, in addition to descriptive statistical methods 
(mean±standard deviation), Student’s t-test and the Mann-Whit-
ney U Test were used to establish potential differences between 
the averages of 2 independent groups for parameters with and 
without normal distributions, respectively. Variance analysis of 
intergroup values was performed using the Kruskal-Wallis test. 
The one-way ANOVA test was used for normal distribution, 
one-way variance analysis. Tukey/Bonferroni correction was 
applied to obtain the right group making the difference. Statisti-
cally significant differences were also analyzed with the Dunnett 
test. To determine the potential correlation of RDW with PLT, 
CRP or ESR between multiple groups, Spearman’s rank correla-
tion coefficient was used. Receiver operating characteristic (ROC) 
curve analysis was used to calculate sensitivity and specificity 
levels. For comparisons of qualitative data, the chi-squared test 
was used. The results in the 95% confidence interval and p-
values of less than 0.05 were considered to be significant.
Table 1. Demographic and Clinical Characteristics of the Controls and 
the Patients with IBD
Characteristic
Control 
group (n=44)
CD (n=56) UC (n=61)
Age, yr 38.9±11 38±10 40.3±12
Gender, F/M 21/23 30/26 26/35
Duration of disease, mo - 36.6±30.5 45.6±43.8
Localization of disease, n (%)
   Ileitis  - 10 (17.8) -
   Colitis - 30 (53.5) -
   Ileocolitis - 16 (28.6) -
   Proctitis - - 16 (26.2)
   Left sided - - 12 (19.7)
   Pancolitis - - 33 (54.1)
Clinical activity, n (%)
   Active disease - 29 (51.8) 35 (57.4)
   In remission - 27 (48.2) 26 (42.6)
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative 
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RESULTS
A diagnosis of UC was made in 61 of the 117 IBD patients 
enrolled in the study, and a diagnosis of CD was given to the 
other 56 patients. No significant differences were found between 
the IBD patients or their subgroups enrolled in the study com-
pared with the control group subjects in terms of age or gender. 
Demographic and clinical characteristics of the controls and the 
patients with IBD were shown in Table 1.
The lab test findings from patients with UC or CD compared 
to those from the control group are presented in Tables 2 and 
3. When the IBD patients were compared based on their dis-
ease state, active disease versus in remission, we observed the 
following: 1) regardless of the disease state, the RDW level in 
CD (13.9±1.1) patients was statistically higher than that in UC 
(13.3±0.8) patients (p<0.001); 2) during the remission period, the 
RDW percentages in UC (12.9±0.7) and CD (13.1±0.5) patients 
were not significantly different (p=0.29); 3) the RDW percentage 
in active CD (14.7±1) patients was significantly higher than that 
in patients with active UC (13.5±0.8) (p<0.001); 4) the RDW per-
centage in active CD patients (14.7±1) was significantly higher 
than that in CD patients in remission (13.1±0.5) (p<0.001); and 5) 
the RDW percentage in active UC patients (13.5±0.8)  was sig-
nificantly higher than that in UC patients in remission (12.9±0.7) 
(p<0.001).
The CRP and ESR levels in patients with active CD were 
found to be significantly higher than those in the CD patients 
in remission or in the controls. Similar results were observed 
in patients with active UC versus UC patients in remission. No 
statistically significant differences were found between the CRP 
Table 2. Comparison of Laboratory Parameters in UC Patients and 
Controls (One-Way ANOVA Test)
Parameter
Control 
group 
(n=44)
UC group
p-value Active 
(n=35)
Remission 
(n=26)
RDW, % 12.7±0.4 13.5±0.8 12.9±0.7 <0.001
Hgb, g/dL 14.3±0.96 13.5±0.92 14±1.1 0.004
MCV, fl 87.3±2.4 85.4±3.1 87.2±3.2 0.009
WBC, ×10
3/μL   7.1±1.25   8.0±2.6   6.9±1.5 0.042
PLT, ×10
3/μL  249±45  386±518  271±67 0.123
ESR, mm 6.43±2.1 26.2±12.9 11.1±6.6 <0.001
CRP, mg/dL   0.3±0.16 1.45±1.34 0.59±0.28 <0.001
B12, pg/dL  240±110  260±142  232±72 0.765
Folate, ng/dL   5.9±2.4   5.0±2.9   4.5±1.4 0.009
Transferrin sat., % 32.7±10.6 23.4±9.6 26.8±10.4 <0.001
Albumin, g/dL 4.34±0.18   4.0±0.2   4.3±0.2 <0.001
Ferritin, ng/mL 55±28 70±30    66±28 0.02
UC, ulcerative colitis; RDW, red cell distribution width; Hgb, he-
moglobin; WBC, white blood cell count; PLT, platelet counts; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein.
Table 3. Comparison of Laboratory Parameters in CD Patients and 
Controls (One-Way ANOVA Test)
Parameter
Control 
group (n=44)
CD group
p-value Active 
(n=29)
Remission 
(n=27)
RDW, % 12.7±0.4 14.7±1 13.1±0.5 <0.001
Hgb, gr/dL 14.3±0.96 13.3±0.83 13.7±1 <0.001
MCV, fl 87.3±2.4 84.8±3.6 86.6±3.2 0.002
WBC, ×10
3/μL   7.1±1.25   7.7±1.8   6.3±1.6 0.003
PLT, ×10
3/μL  249±45  327±64  262±55 <0.001
ESR, mm 6.43±2.1 28.3±16.1   9.9±5.3 <0.001
CRP, mg/dL   0.3±0.16 3.39±2.37 0.46±0.3 <0.001
B12, pg/dL  240±110  232±129  213±109 0.414
Folate, ng/dL   5.9±2.4   4.2±1   5.0±1.9 0.004
Transferrin sat., % 32.7±10.6 22.9±12.6 30.7±14.4 <0.001
Albumin, g/dL  4.34±0.18 3.87±0.31 4.26±0.32 <0.001
Ferritin, ng/mL 55±28 82±65 57±20 0.067
CD, Crohn’s disease; RDW, red cell distribution width; Hgb, hemoglo-
bin; WBC, white blood cell count; PLT, platelet counts; ESR, erythro-
cyte sedimentation rate; CRP, C-reactive protein.
Table 4. Correlation of RDW with Other Inflammatory Parameters (Spearman Correlation)
RDW PLT ESR CRP
RDW, % Correlation coefficient 1.000 0.304* 0.351* 0.503*
Significance - 0.001 <0.001 <0.001
PLT, ×10
3/μL Correlation coefficient 0.304* 1.000 0.287* 0.481*
Significance 0.001 - 0.002 <0.001
ESR, mm/hr Correlation coefficient 0.351* 0.287* 1.000 0.676*
Significance <0.001 0.002 - <0.001
CRP, mg/dL Correlation coefficient 0.503* 0.481* 0.676* 1.000
Significance <0.001 <0.001 <0.001 -
RDW, red cell distribution width; PLT, platelet counts; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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and ESR levels of UC patients in remission and CD patients in 
remission. The Spearman correlation (Table 4) showed that in-
creased inflammatory parameters, such as ESR, CRP and PLT, 
were significantly correlated with an elevated RDW level in the 
patients with active phase of their disease. In addition, the in-
flammatory parameters themselves were significantly correlated. 
These data suggest that RDW levels increase in the presence of 
inflammation in a similar fashion to other inflammatory param-
eters; thus, RDW can be considered to be an indicator of active 
inflammation.
Comparisons of the RDW with other inflammatory parameters 
(ESR, CRP, and PLT) in UC patients and the corresponding ROC 
curves are shown in Table 5 and Fig. 1, respectively. For the de-
termination of disease activation in UC patients, the specificity 
for using the RDW as an indicator of active disease in UC pa-
tients was calculated to be 84%, with 17% sensitivity. The most 
sensitive indicator for the active disease state in UC patients was 
ESR (91%), and its specificity was 55%. Overall, in UC patients, 
RDW and PLT levels were not significant indicators of the active 
disease state in terms of sensitivity and specificity, whereas CRP 
and ESR values were statistically significant. In contrast, RDW 
was found to be the most specific test for the determination 
of active disease in CD patients, with 93% specificity and 79% 
sensitivity (Table 6, Fig. 2). The CRP level was the most sensitive 
indicator (93%) for CD patients, but this parameter had only 
64% specificity. Of the inflammatory markers, the sensitivity of 
ESR was found to be 86% for assessing the disease activation 
state in CD patients, with a specificity of 58%. In addition, the 
PLT level was significant in terms of both sensitivity and speci-
ficity. Overall, we found that the determination of the RDW was 
a significantly sensitive and specific method for the assessment 
of the disease activation state of CD, similar to sensitivity and 
specificity of other established inflammatory parameters.
DISCUSSION
The aim of an IBD treatment plan is to induce remission and 
to ensure that the remission is maintained. Currently, research 
in this field is directed toward the identification of tests for 
the assessment of the active disease that are easy to perform, 
affordable, noninvasive and compatible with the equipment 
Table 5. Statistical Data for RDW, PLT, CRP, and ESR in the Active UC Group
AUC (95% CI) Cut-off Sensitivity, % Specificity, % p-value
RDW, % 0.595 (0.496-0.693) 14 17 84 0.087
14.5 17 90
15 3 92
PLT, ×10
3/μL 0.622 (0.504-0.739) 274,000 71 55 0.028
285,500 66 60
306,000 54 75
317,000 51 89
CRP, mg/dL 0.709 (0.620-0.798) 0.75 80 66 <0.001
0.85 69 78
0.95 57 75
1.01 54 79
ESR, mm/hr 0.817 (0.744-0.891) 9.5 91 55 <0.001
10.5 89 60
14.5 83 75
15.5 83 76
RDW, red cell distribution width; PLT, platelet counts; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AUC, area under curve; CI, 
confidence interval; UC, ulcerative colitis.
Fig. 1. ROC curves for PLT, CRP, ESR, and RDW compared with 
the activity level of UC (the area under the curve for RDW is 0.595, 
p=0.087).
ROC, receiver operating characteristic; PLT, platelet counts; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; RDW, red cell 
distribution width; UC, ulcerative colitis.464  Gut and Liver, Vol. 5, No. 4, December 2011
available in the clinic and laboratory. In our study, the potential 
use of RDW as an indicator for the IBD active state and the cor-
relation of RDW with ESR and CRP during active disease were 
investigated. Additionally, a control group was included in the 
study to assess alterations in RDW between these controls and 
the IBD patients. RDW sensitivity and specificity analyses were 
performed on patients with active disease. Significant increases 
in RDW, ESR, and CRP were observed in all groups compared 
to the control group. We also observed a significant increase in 
RDW, ESR and CRP in the active disease periods of both CD and 
UC groups compared to the control group. This therefore dem-
onstrates that there is a correlation between ESR, CRP and RDW 
in IBD.
Testing for RDW values in IBD patients would be an afford-
able method that would not require any additional costs both 
for patient and clinic. Modern hemogram devices automatically 
measure the size of red blood cells and analyze their distribution 
volume. Of the standard, measured lab parameters, RDW has the 
highest sensitivity for diagnosing IDA.
14 Some studies have sug-
gested that the impairment of intestinal iron absorption in CD 
patients correlates with disease activity and inflammatory mark-
ers.
15 RDW is also a sensitive indicator for the assessment of nu-
tritional factors that are critical for the generation and matura-
tion of red blood cells. Nutritional deficiencies result in impaired 
formation of red blood cells, which leads to a heterogeneous red 
blood cell population and an increase in RDW.
16 Accordingly, 
for this study, efforts were made to prevent iron deficiency and 
to select patients who did not have anemia to prevent misevalu-
ation of the RDW, the first parameter to increase in the case of 
iron deficiency; therefore, we measured serum iron, total iron 
binding capacity and ferritin levels, and we calculated transfer-
ring saturation levels in the enrolled patients. In addition, the 
folic acid and B12 levels of the patients were also determined, 
and patients with levels lower than the reference values were 
excluded from the study. Thus, hematological patients who 
would likely have an elevated RDW were eliminated from this 
study to the greatest extent possible. 
In recent years, many studies have investigated alterations in 
RDW in association with cardiac death (especially heart failure) 
Table 6. Statistical Data for RDW, PLT, CRP, and ESR in the Active CD Group
AUC (95% CI) Cut-off Sensitivity, % Specificity, % p-value
RDW, % 0.935 (0.894-0.975) 13.85 79 93 <0.001
13.95 72 94
14.05 66 95
14.7 45 96
PLT, ×10
3/μL 0.732 (0.639-0.826) 271,500 79 54 <0.001
287,000 72 58
291,500 66 65
298,500 62 71
CRP, mg/dL 0.907 (0.831-0.983) 0.65 93 64 <0.001
0.95 93 81
1.15 90 88
2.5 55 97
ESR, mm/hr 0.803 (0.719-0.887) 10.5 86 58 <0.001
14.5 79 71
17.5 66 76
24.5 55 84
RDW, red cell distribution width; PLT, platelet counts; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AUC, area under curve; CI, 
confidence interval; CD, Crohn’s disease.
Fig. 2. ROC curves for PLT, CRP, ESR, and RDW compared with the 
activity level of CD (CDAI below or above 150; area under the curve 
for RDW is 0.935; p<0.001).
ROC, receiver operating characteristic; PLT, platelet counts; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; RDW, red cell 
distribution width; CD, Crohn’s disease; CDAI, CD activity index.Yeşil A, et al: Red Cell Distribution Width and Inflammatory Bowel Disease  465
and noncardiac death.
17-22 These studies have reported a cor-
relation of RDW with ESR and CRP, such that RDW increases 
during inflammation, similar to the increase seen in other in-
flammatory parameters, and have suggested that RDW might 
increase due to chronic inflammation. Lee and Kim
23 investi-
gated the potential correlation of RDW with ESR and CRP in 
patients with the inflammatory disease rheumatoid arthritis and 
found that there was indeed a correlation between RDW and 
CRP in both the anemic and the nonanemic groups. Lippi et 
al.
24 conducted a large-scale cohort study on 3,845 subjects and 
investigated the correlation of RDW with ESR and CRP; it was 
concluded that RDW increased during inflammation, similar to 
the increase seen in other inflammatory parameters.
Although there is a strong precedent for a correlation between 
RDW and chronic inflammation, this relationship has not been 
thoroughly examined in the case of IBD, as there is currently 
only one study on this subject in the scientific literature. In this 
particular study, conducted by Cakal et al.,
25 the correlation be-
tween IBD disease activation state and RDW was investigated. 
This study included a total of 96 patients (74 UC patients and 
22 CD patients) and found that RDW was significantly increased 
during active disease in both UC and CD patients compared 
to the RDW in patients in remission of these diseases. In addi-
tion, a correlation between elevated RDW levels and CRP and 
ESR levels was found. Sensitivity and specificity analysis for 
the RDW test showed that there was 75% sensitivity and 86% 
specificity observed in UC patients and 63% sensitivity and 92% 
specificity observed in CD patients. Thus, it was concluded that 
RDW was significantly higher in active IBD patients and that an 
increase in RDW was the most sensitive and most specific test 
for the determination of active disease in UC patients.
The specificity and sensitivity values determined for active UC 
disease in the study by Cakal et al.
25 were different from those 
observed in our study. The Hgb levels of patients in either an 
active or remission period enrolled in the previous study were 
lower than those of the patients in our study. As rectal bleeding 
and the presence of blood in the feces are often seen in UC pa-
tients, the occurrence of IDA in these patients is more frequent 
(81%). In the Cakal et al. study, ferritin, transferrin saturation, 
serum iron and MCV levels, which we used as criteria for the 
elimination of patients with anemia and IDA, were not inves-
tigated. Therefore, elevated RDW in UC patients with clear IDA 
and/or as an early finding of IDA might have been more easily 
determined in the former study. Furthermore, the small number 
of CD patients enrolled in that study (22 patients, with 14 ac-
tive and 8 in remission) and the probable B12-folate deficiency 
might also account for the differences observed between their 
study and ours. 
In their study, Clarke et al.
26 observed a significant difference 
in RDW values in CD and UC groups without categorizing the 
patients as having active disease or as being in remission. In our 
study, when RDW was investigated in the UC and CD groups, 
and all patients or all active patients were considered, the RDW 
levels of CD patients were significantly higher than those of 
the UC group however, no significant difference was observed 
between the groups of patients in remission. If, as presented in 
previous studies, we consider RDW as an indicator of the sys-
temic inflammatory response, then it may be that the significant 
increase in RDW observed in CD patients is indicating that there 
is systemic involvement in CD, including systemic inflam-
mation, which could contribute to the increased frequency of 
extra-intestinal inflammatory events. In addition, there is a cor-
relation between systemic inflammatory events and the disease 
involvement area in UC; that is, there are more systemic symp-
toms in patients with ulcerative pancolitis. 
Although inflammation was present in the UC and CD pa-
tients in remission, the inflammation was minimal and under 
control, as indicated by the values of RDW, ESR and CRP; no 
significant differences in these values were observed between 
the groups. This finding supports the correlation of the current 
inflammation state with the RDW. Moreover, the increase in 
RDW occurred before alterations in MCV and Hgb, suggesting 
that increased RDW can be used as an early indicator of active 
disease in IBD patients. In both CD and UC patients with active 
disease, the RDW levels were significantly higher than in the 
patients in remission periods for each disease. The significant 
increase in RDW observed in active disease patients could have 
been due to intestinal blood loss that occurs in the active pe-
riod, nutritional deficiencies (absorption, emission and intake 
deficiencies), an elevated cytokine load during inflammation, or 
a decrease in erythropoiesis due to increased interleukin-6.
RDW had statistically significant specificity and sensitivity 
for the determination of active CD, but it did not have a similar 
significance for the determination of active UC. When the upper 
limit for defining the RDW as elevated was set at 14%, it was 
determined that RDW levels were elevated in 32% of active UC 
patients and in 61% of active CD patients. When the sensitivity 
and specificity were calculated using the ROC curve, the sen-
sitivity was 17% with 84% specificity for the determination of 
active UC and 79% with 93% specificity for the determination 
of active CD. Compared to the other evaluated inflammatory 
markers, the RDW test exhibited the highest specificity for the 
determination of CD activation.
When the RDW cutoff value was set at 14%, the RDW could 
be used as a specific indicator for determining the disease activ-
ity in UC and CD patients. Although the sensitivity of this assay 
was low in the UC patients in our study, there was a high speci-
ficity observed in UC patients, and both sensitivity and specific-
ity were high in CD patients; therefore, when the RDW level has 
increased by 14%, this assay is useful for the determination of 
disease activation. We also demonstrated that increases in CRP, 
ESR and PLT levels in both UC and CD patients with active dis-
ease correlated with a concurrent increase in RDW. Thus, similar 
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the RDW will also help clinicians to determine the presence of 
active disease. Nutritional deficiencies and their related anemias 
are frequently observed in the IBD patient group, and due to 
replacement therapies and transfusions, elevated RDW levels 
are also frequently present. Although hemograms are routinely 
performed in nearly all patients, sufficient attention is often not 
paid to the RDW, except for its use in the evaluation of anemia. 
In our study, we showed that an increased RDW is an indicator 
of inflammation in IBD patients and that it increases even more 
clearly during active disease phases. Thus, clinicians should in-
clude an evaluation of the RDW parameter during their assess-
ments of IBD patients.
In conclusion, our study has established that RDW can be 
used to determine the disease activity state of IBD. Without 
any additional cost requirements or effort, a careful clinician 
can evaluate a hemogram acquired at any time throughout 
the course of a patient’s disease and can gain valuable data on 
the disease state. Furthermore, as RDW is a routine hemogram 
parameter that can be determined using an automatic blood 
counting device, it is an easy, accessible and affordable test. 
Future studies are needed to better understand the importance 
of the increased RDW observed in IBD patients with active dis-
ease. In addition, studies conducted on a greater number of ac-
tive IBD patients will help to better determine the magnitude of 
RDW increase that indicates disease activation and to evaluate 
early stage disease response to treatment and clinical follow-up.
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